Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11946484 | 0.92 | MAPT (0.33) | MAPTALDH1A1CYP1A2CYP2C19HTT | |
| SCHEMBL11946485 | 0.81 | GAA (0.35) | ALDH1A1CYP1A2MEN1POLBKMT2A | |
| SCHEMBL14899859 | 0.76 | MEN1 (0.33) | CYP1A2MEN1POLBKMT2AGAA | |
| SCHEMBL20818257 | 0.72 | MRGPRX1 (0.43) | ALDH1A1ATRSMN1; SMN2POLBKMT2A | |
| SCHEMBL14081897 | 0.72 | POLB (0.33) | MAPTALDH1A1CYP1A2MEN1POLB | |
| SCHEMBL22207247 | 0.64 | GAA (0.36) | MAPTALDH1A1CYP1A2CYP2C19POLB | |
| SCHEMBL15728531 | 0.64 | ALDH1A1 (0.36) | MAPTALDH1A1CYP1A2CYP2C19HTT | |
| SCHEMBL26131166 | 0.64 | GAA (0.38) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL20640604 | 0.63 | GAA (0.44) | MAPTALDH1A1CYP1A2CYP2C19HTT | |
| SCHEMBL20817925 | 0.62 | ATR (0.48) | ALDH1A1ATRSMN1; SMN2POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | MAPT 2295/4885ALDH1A1 2437/4885CYP1A2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.